Division of Tropical and Humanitarian Medicine, University of Geneva and Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, 1211, Geneva, Switzerland.
Health Action International, Amsterdam, The Netherlands.
Curr Diab Rep. 2018 Jun 16;18(8):48. doi: 10.1007/s11892-018-1019-z.
The purpose of this review is to highlight the key issues with regard to the value, affordability, and availability of diabetes treatments.
Many of the medicines needed to manage diabetes are available as generics and, if purchased appropriately, can be made affordable to many individuals and systems. With new treatments for diabetes, additional costs to individuals and systems need to be assessed in terms of added clinical benefit and financial impact. As healthcare finances are limited, increased spending on diabetes medicines means fewer resources for other areas of diabetes care or for the population as a whole. This increased expenditure is driven by rising prevalence as well as the cost of newer treatments. With an increasing burden of disease and changing patterns of medicines in the market, we stress the need to focus attention on ensuring access for individuals to essential medicines. Universal health care offers unique opportunity to address the issue of access to medicines and the wider issues surrounding access to diabetes care, but this will require concerted action bringing together governments, civil society and the private sector.
目的:本文旨在强调糖尿病治疗的价值、可负担性和可及性方面的关键问题。
发现:许多治疗糖尿病所需的药物都有仿制药,而且如果购买得当,许多个人和系统都可以负担得起。对于新的糖尿病治疗方法,需要根据附加的临床获益和经济影响来评估个人和系统的额外成本。由于医疗保健资金有限,在糖尿病药物上的增加支出意味着用于其他糖尿病护理领域或整个人群的资源减少。这种支出的增加是由患病率的上升以及较新治疗方法的成本推动的。随着疾病负担的增加和市场上药物模式的变化,我们强调需要关注确保个人获得基本药物的机会。全民医保为解决药物可及性问题以及更广泛的糖尿病护理可及性问题提供了独特的机会,但这需要政府、民间社会和私营部门共同采取协调行动。